CBER’s Marks Pushes for Accelerated Approval in Gene Therapies for Rare Diseases

Peter Marks, director of CBER, is pushing to get more gene therapies targeting rare diseases to apply for accelerated approval (AA) to give the promising space a leg up in development.
Source: Drug Industry Daily